Matricelf Ltd. seeks FDA feedback ahead of Nasdaq dual listing
What happened
Matricelf Ltd., a regenerative medicine company, announced it is seeking FDA feedback regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange and plans a dual listing on Nasdaq to support its transition into first in human studies. Matricelf has reported completing its GLP safety study and initiating GMP manufacturing activities.
From pr-inside.com
Why it matters
The company is preparing for a major market expansion by pursuing a dual listing on Nasdaq. This move supports the company's progression toward human clinical programs for its personalized neural tissue transplant, which is intended to replace damaged neural tissue following traumatic spinal cord injury.
From pr-inside.com
Who's involved
- FDARegulatory body that provided written feedback supporting key elements of the proposed trial design.
- Tel Aviv Stock ExchangeStock exchange where Matricelf Ltd. is currently listed.
- NasdaqAmerican stock exchange where Matricelf Ltd. plans to execute a dual listing.
Keep exploring
The entities involved
- FDA
-
Tel Aviv Stock Exchange
stock exchange located in Tel Aviv, Israel
-
Nasdaq
American fully electronic stock exchange
Related events
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.